Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

Autor: San-Miguel, J. Avet-Loiseau, H. Paiva, B. Kumar, S. Dimopoulos, M.A. Facon, T. Mateos, M.-V. Touzeau, C. Jakubowiak, A. Usmani, S.Z. Cook, G. Cavo, M. Quach, H. Ukropec, J. Ramaswami, P. Pei, H. Qi, M. Sun, S. Wang, J. Krevvata, M. DeAngelis, N. Heuck, C. Van Rampelbergh, R. Kudva, A. Kobos, R. Qi, M. Bahlis, N.J.

In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/mel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::9171ad68441f80d41018dc420b6da8d2
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:2999635

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Autor: Kaufman, J.L. (Jonathan L.), Dimopoulos, M.A. (Meletios A.), White, D.J. (Darrell J.), Benboubker, L. (Lotfi), Cook, G. (Gordon), Leiba, M. (Merav), Morton, J. (James), Takezako, N. (Naoki), Kim, K. (Kihyun), Moreau, P. (Philippe), Sutherland, H.J. (Heather J.), Magen, H. (Hila), Iida, S. (Shinsuke), Kim, J.S. (Jin Sheok), Prince, H.M. (H. Miles), Cochrane, T. (Tara), Oriol, A. (Albert), O’Rourke, L. (Lisa), Trivedi, S. (Sonali), Casneuf, T. (Tineke), Krevvata, M. (Maria), Ukropec, J. (Jon), Kobos, R. (Rachel), Avet-Loiseau, H. (Herve), Usmani, S.Z. (Saad Z.), San-Miguel, J.F. (Jesús F.)

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1111::9b16e674b3429fb429d3b9686dcdd063
https://hdl.handle.net/10171/65790

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX

Autor: Kaufman, J. L., Dimopoulos, M., White, D., Benboubker, L., Cook, G., Leiba, M., Morton, J., Joy Ho, P., Kim, K., Takezako, N., Moreau, P., Sutherland, H. J., Magen, H., Iida, S., Kim, J. S., Miles Prince, H., Cochrane, T., Oriol, Albert, Bahlis, N. J., Chari, A., O'Rourke, L., Trivedi, S., Casneuf, T., Krevvata, M., Ukropec, J., Kobos, R., Avet-Loiseau, H., Usmani, S. Z., San-Miguel, J., Universitat Autònoma de Barcelona

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-10 (2020)
Blood Cancer Journal
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory mu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf52c1b21c245ed4d385bb3826621820
https://ddd.uab.cat/record/236598